WO1999061057A3 - Molecules targeting cd40 and tumor cells - Google Patents

Molecules targeting cd40 and tumor cells Download PDF

Info

Publication number
WO1999061057A3
WO1999061057A3 PCT/US1999/011421 US9911421W WO9961057A3 WO 1999061057 A3 WO1999061057 A3 WO 1999061057A3 US 9911421 W US9911421 W US 9911421W WO 9961057 A3 WO9961057 A3 WO 9961057A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
tumor cell
cells
tumor cells
specificity
Prior art date
Application number
PCT/US1999/011421
Other languages
French (fr)
Other versions
WO1999061057A2 (en
Inventor
David W Thomas
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Priority to AU40098/99A priority Critical patent/AU4009899A/en
Publication of WO1999061057A2 publication Critical patent/WO1999061057A2/en
Publication of WO1999061057A3 publication Critical patent/WO1999061057A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Disclosed are molecules having one specificity for CD40 and the other for a tumor cell antigen. The molecules may be bispecific, or multispecific, antibodies. The molecules are useful for treating cancer and tumors. Where the tumor cell specificity is directed against a tumor cell surface antigen of sufficient density, upon in vivo administration, a number of bispecific molecules will bind to the tumor cell surface and present, in sum, multivalency for the CD40-expressing cells. The multivalent anti-CD40 can now ligate CD40 on adjacent CD40-expressing cells (e.g., macrophages, dendritic cells, B-lymphocytes, and others), resulting in activation of these CD40 cells, which aid in eliminating the tumor.
PCT/US1999/011421 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells WO1999061057A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40098/99A AU4009899A (en) 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8662398P 1998-05-23 1998-05-23
US60/086,623 1998-05-23

Publications (2)

Publication Number Publication Date
WO1999061057A2 WO1999061057A2 (en) 1999-12-02
WO1999061057A3 true WO1999061057A3 (en) 2000-04-06

Family

ID=22199807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011421 WO1999061057A2 (en) 1998-05-23 1999-05-21 Molecules targeting cd40 and tumor cells

Country Status (2)

Country Link
AU (1) AU4009899A (en)
WO (1) WO1999061057A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3662101A (en) * 2000-02-01 2001-08-14 Tanox Inc Cd40-binding apc-activating molecules
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
SI2647707T1 (en) 2010-11-30 2018-12-31 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2015156268A1 (en) 2014-04-07 2015-10-15 中外製薬株式会社 Immunoactivating antigen-binding molecule
BR112016026299A2 (en) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
BR112018076260A2 (en) 2016-06-20 2019-03-26 Kymab Limited antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin
EP3708589A4 (en) 2017-11-08 2021-08-11 Kyowa Kirin Co., Ltd. BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM
CN113677703A (en) * 2018-12-17 2021-11-19 鳄鱼生物科学公司 Polypeptides
AU2020276931A1 (en) 2019-05-15 2021-12-16 Kyowa Kirin Co., Ltd. Bispecific antibody binding to CD40 and FAP
EP3971293A4 (en) 2019-05-15 2023-02-08 Kyowa Kirin Co., Ltd. Bispecific antibody capable of binding to cd40 and gpc3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534254A (en) * 1992-02-06 1996-07-09 Chiron Corporation Biosynthetic binding proteins for immuno-targeting

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534254A (en) * 1992-02-06 1996-07-09 Chiron Corporation Biosynthetic binding proteins for immuno-targeting

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BANCHEREAU J. ET AL: "Long-term human B cell lines dependent on interleukin-4 and antibody to CD40", SCIENCE, vol. 251, 4 January 1991 (1991-01-04), pages 70 - 71, XP002923599 *
CLARK E.A. ET AL: "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 83, no. 12, June 1986 (1986-06-01), USA, pages 4494 - 4498, XP002108667 *
HIRANO A. ET AL: "Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand", BLOOD, vol. 93, no. 9, 1 May 1999 (1999-05-01), pages 2999 - 3007, XP002923598 *
KOLLET O. ET AL: "Idiotype-specific inhibition of LFA-1-mediated cell adhesion by anti-idiotype x anti-LFA-1 bispecific antibodies", IMMUNOLOGY LETTERS, vol. 62, 1998, pages 171 - 176, XP002923600 *

Also Published As

Publication number Publication date
WO1999061057A2 (en) 1999-12-02
AU4009899A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
WO1999061057A3 (en) Molecules targeting cd40 and tumor cells
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
WO1998051337A3 (en) Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
DK0768885T3 (en) Method of inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
AP2092A (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
WO2006130773A3 (en) Methods of treating brain tumors with antibodies
WO2001040309A3 (en) Anti-prostate stem cell antigen (psca) antibody compositions and methods of use
CA2291065A1 (en) Raf kinase inhibitors
WO2004050707A3 (en) Tumor-specific recognition molecules
ID28623A (en) TURUNAN 2-AMINO-TIAZOL, THE PROCESS OF MAKING, AND THE USE AS ANTI-TUMOR
ID28971A (en) TURUNAN 2-UREIDO-TIAZOL, THE PROCESS OF MAKING, AND THE USE AS ANTI-TUMOR
ID21529A (en) METHODS AND COMPOSITIONS FOR TUMOR TREATMENT, PREVENTION, RELATIONSHIP RELATED TO TUMORS AND COCOEX
HK1093690A1 (en) Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2000002584A3 (en) Cancer treatment methods using antibodies to aminophospholipids
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
WO2005085861A3 (en) Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
WO2000045853A3 (en) Treatment of tumors with genetically engineered herpes virus
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
IE810451L (en) Tumour localization with labeled antibodies
MXPA01008137A (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase.
WO2003064620A3 (en) Hepsin substrates and prodrugs
AU2407899A (en) Monoclonal antibody which recognizes the oligosaccharide n-glycolylated-galactose-glucose sialic acid in malignant tumors, and composition containing it
WO2005019435A8 (en) Anti-cancer vaccines
WO2003026490A3 (en) Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
WO2001024684A3 (en) Methods for treatment of solid tumors and metastasis by gene therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase